Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Stanford, California Clear all
Completed Not applicable Interventional Results available

Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.

NCT01135186
View directory record Official record
Conditions
Gastroparesis
Interventions
sapropterin dihydrochloride
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis

NCT00762073
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
budesonide, placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
2 Years to 18 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00078403
View directory record Official record
Conditions
HIV Infections, Hepatitis C, Liver Disease
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

NCT04843761
View directory record Official record
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jun 7, 2026, 4:59 AM EDT
Active, not recruiting No phase listed Observational

The REPLACE Registry for Cholbam® (Cholic Acid)

NCT03115086
View directory record Official record
Conditions
Bile Acid Synthesis Disorders
Interventions
Cholbam
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2039
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Jun 7, 2026, 4:59 AM EDT
Completed No phase listed Observational

Collecting Tumor Samples From Patients With Gynecological Tumors

NCT00897442
View directory record Official record
Conditions
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Childhood Embryonal Rhabdomyosarcoma, Childhood Malignant Ovarian Germ Cell Tumor, Endometrioid Stromal Sarcoma, Gestational Trophoblastic Tumor, Malignant Mesothelioma, Malignant Ovarian Epithelial Tumor, Melanoma, Neoplasm of Uncertain Malignant Potential, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Paget Disease of the Vulva, Recurrent Cervical Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Cervical Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Cervical Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Uterine Corpus Cancer, Uterine Corpus Leiomyosarcoma, Vulvar Squamous Cell Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
187
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

NCT00233454
View directory record Official record
Conditions
Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)
Interventions
Midostaurin
Drug
Lead sponsor
Jason Robert Gotlib
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Not applicable Interventional

Erector Spinae Plane Versus Interscalene Blocks for Shoulder Surgery

NCT03807505
View directory record Official record
Conditions
Anesthesia, Local, Phrenic Nerve Paralysis, Upper Extremity Injury, Shoulder Injury
Interventions
Interscalene brachial plexus nerve block, Erector spinae plane block
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past

NCT00001029
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
35
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 7, 2026, 4:59 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome

NCT01880437
View directory record Official record
Conditions
Myelodysplastic Syndromes, Myelogenous Leukemia, Acute
Interventions
cytarabine, vismodegib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Stanford, California • Ann Arbor, Michigan • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Jun 7, 2026, 4:59 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Prediabetes Stratification by Multi-omics Profile After Food Intake

NCT06005051
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, PreDiabetes
Interventions
Dietary intervention
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

NCT01327053
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
LDE225
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
22
States / cities
Fayetteville, Arkansas • Los Angeles, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jun 7, 2026, 4:59 AM EDT
Suspended Not applicable Interventional

Vibratory Stimulation for the Treatment of Chronic Pain

NCT04069572
View directory record Official record
Conditions
Chronic Pain, Pelvic Pain, Functional Abdominal Pain Syndrome, Low Back Pain, Migraine
Interventions
Vibrotactile Stimulation, Sham Stimulation
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Not applicable Interventional

Food for Health Equity: Evaluation of a Nutrition Assistance Program

NCT05947357
View directory record Official record
Conditions
Cancer
Interventions
Nutrition Assistance Program
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Use of Apple Watch Features for Identification of Cardiac Arrhythmias

NCT03769207
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmias, Cardiac, Atrial Flutter
Interventions
Ambulatory ECG
Device
Lead sponsor
Apple Inc.
Industry
Eligibility
22 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jun 7, 2026, 4:59 AM EDT
Terminated Phase 3 Interventional

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

NCT03616470
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Uproleselan, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Jun 7, 2026, 4:59 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

NCT06892639
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
D-Fi
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
4
States / cities
Redwood City, California • Santa Margarita, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jun 7, 2026, 4:59 AM EDT
Terminated Phase 1 Interventional

Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures

NCT01987375
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cetuximab-IRDye800
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
19 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Jun 7, 2026, 4:59 AM EDT
Terminated Phase 3 Interventional Results available

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

NCT02312206
View directory record Official record
Conditions
Primary Systemic (AL) Amyloidosis
Interventions
NEOD001, Placebo
Drug · Other
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
32
States / cities
Scottsdale, Arizona • Duarte, California • Stanford, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jun 7, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies

NCT00226655
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
hCRF [XERECEPT (corticorelin acetate injection)]
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
25
States / cities
Phoenix, Arizona • Newport Beach, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Jun 7, 2026, 4:59 AM EDT
Terminated Phase 3 Interventional Results available

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

NCT01522443
View directory record Official record
Conditions
Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
Interventions
cabozantinib, mitoxantrone, prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older · Male only
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
49
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Jun 7, 2026, 4:59 AM EDT
Enrolling by invitation Not applicable Interventional

ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

NCT05932615
View directory record Official record
Conditions
Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Interventions
Navitor Transcatheter Aortic Valve Implantation (TAVI) System, Any Commercially Available Transcatheter Aortic Valve (CAV) System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 7, 2026, 4:59 AM EDT
No Longer Available No phase listed Expanded access

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

NCT01947608
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
LDK378
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Jun 7, 2026, 4:59 AM EDT
Recruiting Phase 1 Interventional

Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction

NCT05068674
View directory record Official record
Conditions
Chronic Ischemic Left Ventricular Dysfunction
Interventions
Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells, Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells, Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells
Drug
Lead sponsor
Joseph C. Wu
Other
Eligibility
21 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jun 7, 2026, 4:59 AM EDT